Eldelumab
Based on 1 Customer Validation
Eldelumab (BMS-936557; MDX-1100) is a fully human IgG1 monoclonal antibody targeting IP-10 (CXCL10). Eldelumab binds and neutralizes IP-10, blocking TNF-α induction, disruption of endothelial junctional complexes, integrin activation, and activated T cell migration. Eldelumab selectively reduces TNF-α release in infected endothelial cells and restores Claudin5, Occludin, ZO-1, and VE-Cadherin expression. Eldelumab can be used for research on hand, foot, and mouth disease (HFMD) and ulcerative colitis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.50%
- CAS No.: 946414-98-8
- Masse moléculaire:146.64 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
Isotype
Human IgG1(K214R) kappa
Recommend Isotype Controls
Species Reactivity
Human
|
IP-10 (CXCL10) |
TNF-α |
Claudin5 |
Occludin |
ZO-1 |
VE-Cadherin |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Scratch/Wound-Healing Migration Assay
- RNA extraction experimental
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Research Protocol for Cancer Immunology
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- DSS-Induced Colitis
- Transwell/Boyden Chamber Migration Assay
- TNBS-Induced Colitis
- Endothelial Tube Formation Assay
- 3D Collagen/Hydrogel Matrix Migration Assay
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IP-10/CXCL10 Protein can bind Eldelumab. The EC50 for this effect is 1.68 ng/mL.
Chemical Information
-
CAS No. 946414-98-8
-
Appearance Liquid
-
Masse moléculaire 146.64 kDa
-
Color Colorless to light yellow
-
SMILES
[Eldelumab]
-
Synonyms
BMS-936557; MDX-1100
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Eldelumab
- 946414-98-8
- BMS-936557
- MDX-1100
- BMS936557
- BMS 936557
- MDX1100
- MDX 1100
- MDX-1100
- CXCR
- TNF Receptor
- CXC chemokine receptors
- C-X-C motif chemokine receptors
- Tumor Necrosis Factor Receptor
- TNFR
- CXCL10
- Claudin5
- Occludin
- T-cell migration
- TNF-α
- VE-Cadherin
- ZO-1
- endothelial junctional complex
- hand
- foot and mouth disease
- ulcerative colitis
- Inhibitor
- inhibitor
- inhibit